1.11
-0.08 (-6.72%)
| Previous Close | 1.19 |
| Open | 1.15 |
| Volume | 1,632,009 |
| Avg. Volume (3M) | 1,198,919 |
| Market Cap | 56,324,840 |
| Price / Book | 0.430 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 - 19 May 2025 |
| Diluted EPS (TTM) | -2.34 |
| Total Debt/Equity (MRQ) | 10.24% |
| Current Ratio (MRQ) | 6.15 |
| Operating Cash Flow (TTM) | -88.22 M |
| Levered Free Cash Flow (TTM) | -54.51 M |
| Return on Assets (TTM) | -35.66% |
| Return on Equity (TTM) | -59.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Cabaletta Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 1.13 |
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.17% |
| % Held by Institutions | 76.72% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Superstring Capital Management Lp | 31 Dec 2024 | 822,293 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Guggenheim, 2,152.25%) | Buy |
| 25.00 (HC Wainwright & Co., 2,152.25%) | Buy | |
| Median | 17.50 (1,476.58%) | |
| Low | 3.00 (Wells Fargo, 170.27%) | Hold |
| Average | 15.83 (1,326.13%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 0.780 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 16 May 2025 | 13.00 (1,071.17%) | Buy | 0.000 |
| Guggenheim | 16 May 2025 | 25.00 (2,152.25%) | Buy | 0.000 |
| 15 May 2025 | 25.00 (2,152.25%) | Buy | 0.000 | |
| HC Wainwright & Co. | 01 Apr 2025 | 25.00 (2,152.25%) | Buy | 1.17 |
| Morgan Stanley | 01 Apr 2025 | 22.00 (1,881.98%) | Buy | 1.17 |
| UBS | 01 Apr 2025 | 7.00 (530.63%) | Buy | 1.17 |
| Wells Fargo | 01 Apr 2025 | 3.00 (170.27%) | Hold | 1.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 May 2025 | Announcement | Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts |
| 31 Mar 2025 | Announcement | Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 19 Mar 2025 | Announcement | Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform |
| 26 Feb 2025 | Announcement | Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |